Crossmark

Pirfenidone improves survival in IPF: results from a real-life study

Crossref DOI link: https://doi.org/10.1186/s12890-018-0736-z

Published Online: 2018-11-23

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Margaritopoulos, George A.

Trachalaki, Athina https://orcid.org/0000-0002-3045-9387
Wells, Athol U.

Vasarmidi, Eirini

Bibaki, Eleni

Papastratigakis, George

Detorakis, Stathis

Tzanakis, Nikos

Antoniou, Katerina M.
License Information

Text and Data Mining valid from 2018-11-23
More Information

Article History

Received: 25 June 2018

Accepted: 7 November 2018

First Online: 23 November 2018

Ethics approval and consent to participate

: Informed consent was obtained from all patients included in the UHH cohort. The study was approved by the Ethics Committees of the University Hospital of Herakleion (IRB number: 17030). Due to the retrospective nature of the analysis of the RBH cohort<sup>13</sup>, ethics committee approval was not required.

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.